These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11882066)

  • 1. Zolpidem in progressive supranuclear palsy.
    Mayr BJ; Bonelli RM; Niederwieser G; Költringer P; Reisecker F
    Eur J Neurol; 2002 Mar; 9(2):184-5. PubMed ID: 11882066
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of zolpidem in the treatment of progressive supranuclear palsy.
    Cotter C; Armytage T; Crimmins D
    J Clin Neurosci; 2010 Mar; 17(3):385-6. PubMed ID: 20071178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zolpidem in progressive supranuclear palsy.
    Daniele A; Moro E; Bentivoglio AR
    N Engl J Med; 1999 Aug; 341(7):543-4. PubMed ID: 10447452
    [No Abstract]   [Full Text] [Related]  

  • 4. Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
    Růzicka E; Roth J; Jech R; Busek P
    Mov Disord; 2000 Jul; 15(4):734-5. PubMed ID: 10928588
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of the Meige syndrome with oral zolpidem monotherapy.
    An JY; Kim JS; Kim YI; Lee KS
    Mov Disord; 2008 Aug; 23(11):1619-21. PubMed ID: 18581473
    [No Abstract]   [Full Text] [Related]  

  • 6. Zolpidem therapy for movement disorders.
    Abe K
    Recent Pat CNS Drug Discov; 2008 Jan; 3(1):55-60. PubMed ID: 18221242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolpidem-related epileptic seizures: a case report.
    Tripodianakis J; Potagas C; Papageorgiou P; Lazaridou M; Matikas N
    Eur Psychiatry; 2003 May; 18(3):140-1. PubMed ID: 12763302
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug induced arousal from the permanent vegetative state.
    Clauss R; Nel W
    NeuroRehabilitation; 2006; 21(1):23-8. PubMed ID: 16720934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progressive supranuclear palsy, diagnostic problems in the light of own case].
    Kulczycki J; Kuran W
    Neurol Neurochir Pol; 1998; 32(6):1513-22. PubMed ID: 10358839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
    Olubodun JO; Ochs HR; von Moltke LL; Roubenoff R; Hesse LM; Harmatz JS; Shader RI; Greenblatt DJ
    Br J Clin Pharmacol; 2003 Sep; 56(3):297-304. PubMed ID: 12919178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zolpidem increases bladder capacity and decreases urine excretion in rats.
    Yokoyama O; Matsuta Y; Yanai-Inamura H; Watanabe M; Ohtake A; Suzuki M; Sasamata M
    Neurourol Urodyn; 2010 Apr; 29(4):587-91. PubMed ID: 19760758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam.
    Vlainić J; Pericić D
    Neuropharmacology; 2009 Jun; 56(8):1124-30. PubMed ID: 19345234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy.
    Polo KB; Jabbari B
    Ann Neurol; 1994 Feb; 35(2):237-9. PubMed ID: 8109906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term treatment of progressive supranuclear palsy with amitriptyline].
    Yamashi M; Sanada J; Miyazaki Y; Ikeda H
    Rinsho Shinkeigaku; 1986 Nov; 26(11):1138-41. PubMed ID: 3829513
    [No Abstract]   [Full Text] [Related]  

  • 16. [Zolpidem (ivadal) treatment of sleep disorders].
    Aleksandrovskiĭ IuA; Androsova VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(9):22-6. PubMed ID: 11586699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole in progressive supranuclear palsy.
    Weiner WJ; Minagar A; Shulman LM
    Neurology; 1999 Mar; 52(4):873-4. PubMed ID: 10078747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing.
    Modreanu R; Özdemir G; Buhmann C; Hauptmann B
    J Neurol Sci; 2018 May; 388():139-140. PubMed ID: 29627008
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.